• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: "Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC".

作者信息

Ben Khaled Najib, Mayerle Julia, De Toni Enrico N, Geier Andreas, Reiter Florian P

机构信息

Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.

Division of Hepatology, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany.

出版信息

JHEP Rep. 2024 Jun 17;6(8):101146. doi: 10.1016/j.jhepr.2024.101146. eCollection 2024 Aug.

DOI:10.1016/j.jhepr.2024.101146
PMID:39105182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11298808/
Abstract
摘要

相似文献

1
Response to: "Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC".对《在晚期肝癌全身治疗下，抗凝与静脉曲张出血风险增加无关》的回应
JHEP Rep. 2024 Jun 17;6(8):101146. doi: 10.1016/j.jhepr.2024.101146. eCollection 2024 Aug.
2
Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC.在晚期肝癌的全身治疗中，抗凝治疗与静脉曲张出血风险增加无关。
JHEP Rep. 2024 May 16;6(8):101120. doi: 10.1016/j.jhepr.2024.101120. eCollection 2024 Aug.
3
Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion.对于合并 HCC 和大血管肿瘤侵犯的患者，管理静脉曲张但不抗凝与改善预后相关。
Cancer Imaging. 2024 Jan 13;24(1):9. doi: 10.1186/s40644-024-00657-z.
4
HCC portal hypertension imaging score derived from CT predicts re-bleeding and mortality after acute variceal bleeding.基于 CT 的 HCC 门脉高压影像学评分可预测急性静脉曲张出血后的再出血和死亡率。
Cancer Imaging. 2024 Mar 28;24(1):45. doi: 10.1186/s40644-024-00689-5.
5
Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding.出现静脉曲张出血的肝细胞癌患者的预后
Am J Gastroenterol. 2004 Nov;99(11):2158-65. doi: 10.1111/j.1572-0241.2004.40336.x.
6
Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial.早期抗凝治疗对伴有急性静脉曲张出血的门静脉血栓形成患者是安全的：一项多中心随机对照试验。
Intern Emerg Med. 2023 Mar;18(2):513-521. doi: 10.1007/s11739-023-03206-x. Epub 2023 Jan 24.
7
Endoscopic ultrasound-guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage.内镜超声引导下氰基丙烯酸酯注射预防静脉曲张出血的肝细胞癌患者再出血。
J Gastroenterol Hepatol. 2020 Dec;35(12):2192-2201. doi: 10.1111/jgh.15168. Epub 2020 Jul 9.
8
Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study.肝细胞癌门静脉侵犯会加重静脉曲张出血：一项配对巢式病例对照研究。
BMC Cancer. 2021 Jan 5;21(1):11. doi: 10.1186/s12885-020-07708-1.
9
The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients.经肝动脉化疗栓塞术后肝细胞癌患者静脉曲张出血的发生率及预测因素。
J Formos Med Assoc. 2020 Feb;119(2):635-643. doi: 10.1016/j.jfma.2019.08.019. Epub 2019 Sep 5.
10
Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma.原发性静脉曲张出血的一级预防与新诊断肝细胞癌患者生存率的提高
Dig Dis Sci. 2016 Nov;61(11):3354-3362. doi: 10.1007/s10620-016-4255-6. Epub 2016 Jul 19.

本文引用的文献

1
Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC.在晚期肝癌的全身治疗中，抗凝治疗与静脉曲张出血风险增加无关。
JHEP Rep. 2024 May 16;6(8):101120. doi: 10.1016/j.jhepr.2024.101120. eCollection 2024 Aug.
2
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.阿替利珠单抗/贝伐珠单抗或乐伐替尼治疗肝细胞癌：聚焦出血和血栓栓塞事件的多中心真实世界研究
JHEP Rep. 2024 Apr 8;6(6):101065. doi: 10.1016/j.jhepr.2024.101065. eCollection 2024 Jun.
3
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab.血管内皮生长因子（VEGF）通路抑制剂联合免疫检查点抑制剂（ICI）在晚期肝细胞癌（HCC）的治疗中取得了较好的疗效。然而，血管内皮生长因子（VEGF）通路抑制剂联合免疫检查点抑制剂（ICI）在伴有门静脉高压（PH）的 HCC 患者中的疗效尚不清楚。
Dig Liver Dis. 2024 Sep;56(9):1621-1630. doi: 10.1016/j.dld.2024.02.018. Epub 2024 Mar 27.
4
Treatment of portal hypertension in patients with HCC in the era of Baveno VII.巴韦诺 VII 时代肝癌患者门静脉高压的治疗
J Hepatol. 2023 Mar;78(3):658-662. doi: 10.1016/j.jhep.2022.11.019. Epub 2022 Nov 30.
5
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
6
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.肝硬化门静脉高压症：病理生理机制与治疗
JHEP Rep. 2021 Jun 4;3(4):100316. doi: 10.1016/j.jhepr.2021.100316. eCollection 2021 Aug.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.β 受体阻滞剂预防有临床显著门静脉高压症的肝硬化失代偿（PREDESCI）：一项随机、双盲、安慰剂对照、多中心试验。
Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22.